

**Tirzepatide Was Associated with Improved Health-related Quality of Life in Adults with Obesity or
Overweight and Type 2 Diabetes: Results from Phase 3 SURMOUNT-2 Trial**

Theresa Hunter Gibble¹, Dachuang Cao¹, Xiaotian Michelle Zhang¹, Neena Agarwal Xavier¹, Jiat Ling Poon¹, Angela Fitch²

Affiliations

¹ Eli Lilly and Company, Indianapolis, IN, USA

² Knownwell, 15 Oak St Suite 3, Needham, MA, USA

Corresponding author:

Theresa Hunter Gibble

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, IN 46285, USA

Email: hunter_theresa_marie@lilly.com

Phone: +1 (317) 6510341

Supplementary Table S1. Baseline patient-reported outcomes by bodyweight target achieved and baseline PGIS category

	Weight target achieved							Baseline PGIS category	
HRQoL score, mean (SD)	<5%	≥5%	≥10%	≥15%	≥20%	≥25%	≥30%	Without limitations	With limitations
<i>SF-36v2</i>	<i>n=36</i>	<i>n=515</i>	<i>n=423</i>	<i>n=291</i>	<i>n=172</i>	<i>n=87</i>	<i>n=42</i>	<i>n=423</i>	<i>n=128</i>
Mental Component Score	50.4 (9.8)	52.8 (8.2)	52.8 (8.1)	52.5 (8.6)	52.8 (8.4)	53.5 (7.1)	53.7 (7.4)	54.2 (6.8)	47.4 (10.5)
Physical Component Score	51.1 (6.5)	48.8 (7.9)	48.8 (7.8)	48.1 (7.9)	47.7 (8.2)	48.3 (7.5)	46.7 (8.7)	51.4 (6.1)	40.9 (7.4)
Domain scores (norm-based)									
Physical Functioning	50.3 (7.7)	48.2 (8.5)	48.0 (8.3)	47.5 (8.3)	47.2 (8.6)	48.1 (7.5)	47.3 (8.5)	50.8 (6.8)	39.8 (8.1)
Role-Physical	50.9 (7.0)	50.0 (8.4)	50.0 (8.4)	49.6 (8.5)	49.4 (8.6)	50.3 (7.6)	49.7 (7.9)	52.6 (6.1)	41.9 (9.4)
Bodily Pain	52.1 (9.2)	50.6 (9.7)	50.5 (9.9)	49.6 (10.2)	49.0 (10.5)	49.9 (9.9)	47.8 (11.3)	53.3 (8.2)	41.9 (9.2)
General Health	48.3 (8.6)	48.5 (8.2)	48.7 (8.1)	48.2 (8.4)	48.4 (8.5)	48.5 (8.3)	47.1 (9.1)	50.1 (7.6)	43.2 (8.0)
Vitality	54.0 (9.3)	54.8 (8.5)	54.8 (8.4)	54.2 (8.8)	54.0 (8.7)	53.6 (8.1)	53.5 (8.3)	57.0 (7.3)	47.5 (8.5)
Social Functioning	52.3 (7.1)	51.8 (7.8)	51.7 (7.9)	51.3 (8.1)	51.5 (8.0)	52.9 (6.5)	51.8 (7.3)	53.6 (6.2)	46.2 (9.4)
Role-Emotional	47.7 (10.9)	49.2 (9.5)	49.2 (9.5)	48.7 (10.0)	48.9 (10.2)	50.5 (7.9)	49.8 (8.2)	51.3 (7.3)	41.7 (12.4)
Mental Health	50.4 (9.1)	52.4 (8.0)	52.4 (7.9)	52.1 (8.0)	52.2 (8.0)	52.5 (7.4)	53.1 (7.7)	53.9 (7.0)	46.7 (9.1)
<i>IWQOL-Lite-CT</i>	<i>n=36</i>	<i>n=515</i>	<i>n=422</i>	<i>n=290</i>	<i>n=170</i>	<i>n=85</i>	<i>n=41</i>	<i>n=423</i>	<i>n=128</i>
Total score	74.7 (18.9)	69.7 (21.9)	69.6 (21.8)	67.6 (22.5)	67.2 (23.5)	69.1 (21.8)	68.0 (22.1)	75.9 (18.0)	50.7 (22.0)
Physical Function Composite score	71.3 (23.9)	64.8 (25.5)	64.8 (25.4)	62.5 (25.7)	60.9 (27.2)	62.9 (26.9)	60.2 (27.0)	72.9 (20.3)	39.8 (24.0)
Physical Composite score	70.5 (22.6)	64.5 (24.5)	64.5 (24.4)	62.4 (24.7)	61.2 (26.0)	63.5 (24.6)	61.1 (25.3)	72.4 (19.4)	40.2 (23.0)
Psychosocial Composite score	76.9 (20.0)	72.5 (23.0)	72.4 (22.8)	70.5 (23.9)	70.4 (24.8)	72.2 (22.9)	71.7 (22.8)	77.7 (19.9)	56.4 (24.4)
<i>EQ-5D-5L</i>	<i>n=36</i>	<i>n=510</i>	<i>n=418</i>	<i>n=287</i>	<i>n=169</i>	<i>n=85</i>	<i>n=41</i>	<i>n=417</i>	<i>n=129</i>
EQ-5D-5L Health State Index (UK)	0.9 (0.1)	0.8 (0.2)	0.8 (0.2)	0.8 (0.2)	0.8 (0.2)	0.8 (0.2)	0.8 (0.2)	0.9 (0.1)	0.7 (0.2)
	<i>n=36</i>	<i>n=511</i>	<i>n=419</i>	<i>n=288</i>	<i>n=170</i>	<i>n=86</i>	<i>n=42</i>	<i>n=418</i>	<i>n=129</i>
EQ VAS score	74.9 (15.4)	74.3 (15.5)	74.0 (15.7)	72.8 (16.3)	73.2 (17.0)	73.8 (16.0)	73.6 (16.0)	77.3 (13.4)	64.7 (17.7)

Efficacy Analysis Set-tripeptide-treated participants (all doses pooled). The analysis includes participants with a non-missing baseline and at least one non-missing post-baseline value.

ED-5D-5L = EuroQol 5 Dimension 5 Level; IWQOL-Lite-CT = Impact of Weight on Quality of Life-Lite Clinical Trials; LOCF = last observation carried forward; n = number of participants with non-missing baseline and at least one non-missing post-baseline value; PGIS = Patient Global Impression Status; SD = standard deviation; SF-36v2 = Short Form-36 Health Survey, Version 2